Neximmune announces presentation of preliminary phase 1/2 clinical data at the 2021 american society of clinical oncology annual meeting

Gaithersburg, md., may 19, 2021 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today announced that clinical data from its phase 1/2 dose escalation study of nexi-001 will be presented in a poster session at the american society of clinical oncology (asco) 2021 annual meeting being held virtually from june 4 – june 8, 2021.
NEXI Ratings Summary
NEXI Quant Ranking